A PHASE-II STUDY OF TAMOXIFEN COMBINED WITH CISPLATIN-INTERLEUKIN-2 AND ALPHA-INTERFERON IN METASTATIC MELANOMA

被引：5

作者：

ANTOINE, EC

RIXE, O

VUILLEMIN, E

BENHAMMOUDA, A

BOREL, C

GHIRONZI, GC

MULARONI, E

FRANKS, C

AUCLERC, G

SOUBRANE, C

BANZET, P

WEIL, M

KHAYAT, D

机构：

[1] HOP ST LOUIS,DEPT SURG,PARIS,FRANCE

[2] ROCHE FRANCE LAB,NEUILLY SUR SEINE,FRANCE

[3] EUROCETUS BV,1105 BJ AMSTERDAM,NETHERLANDS

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1995年 / 18卷 / 05期

关键词：

TAMOXIFEN; CISPLATIN; IMMUNOTHERAPY; MELANOMA;

D O I：

10.1097/00000421-199510000-00012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tamoxifen (TAM) has been reported to enhance cisplatin (CDDP) cytotoxicity in experimental and clinical melanoma studies. Based on our previous experience with sequential cisplatin-interleukin-2 (IL2)-interferon (IFN), we performed a phase II study of TAM combined with our original CDDP-IL2-IFN regimen in 22 pretreated metastatic melanoma patients. With a 41% response rate (95% Cl, 21-61) we confirmed the interesting antitumor activity of CDDP-IL2-IFN combination; however, TAM enhanced neither the response rate nor the duration of response, but appeared to induce significantly more myelotoxicity, as compared to our previous results with CDDP-IL2-IFN alone. Whereas mechanisms by which TAM may modulate CDDP cytotoxicity in melanoma tumors remain unknown, the exact place of TAM, if any, and its safety in chemotherapeutic or chemoimmunotherapeutic combinations require further investigations.

引用

页码：421 / 424

页数：4

共 16 条

[1]

BAJETTA E, 1993, P AN M AM SOC CLIN, V12, P393

[2] INTERLEUKIN-2 AND HIGH-DOSE CISPLATIN IN PATIENTS WITH METASTATIC MELANOMA - A PILOT-STUDY [J].

DEMCHAK, PA ;

MIER, JW ;

ROBERT, NJ ;

OBRIEN, K ;

GOULD, JA ;

ATKINS, MB .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) :1821-1830

[3]

FLAHERTY LE, 1991, CANCER, V65, P2471

[4]

HOFMANN J, 1988, P AM ASSOC CANC RES, V29, P481

[5]

JOHNSTON MI, 1984, INTERFERON MECHANISM, V3, P189

[6] SEQUENTIAL CHEMOIMMUNOTHERAPY WITH CISPLATIN, INTERLEUKIN-2, AND INTERFERON ALFA-2A FOR METASTATIC MELANOMA [J].

KHAYAT, D ;

BOREL, C ;

TOURANI, JM ;

BENHAMMOUDA, A ;

ANTOINE, E ;

RIXE, O ;

VUILLEMIN, E ;

BAZEX, PA ;

THILL, L ;

FRANKS, R ;

AUCLERC, G ;

SOUBRANE, C ;

BANZET, P ;

WEIL, M .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2173-2180

[7] CHEMOIMMUNOTHERAPY OF METASTATIC MALIGNANT-MELANOMA THE SALPETRIERE HOSPITAL (SOMPS) EXPERIENCE [J].

KHAYAT, D ;

ANTOINE, E ;

RIXE, O ;

TOURANI, JM ;

VUILLEMIN, E ;

BOREL, C ;

BENHAMMOUDA, A ;

THILL, L ;

FRANKS, C ;

AUCLERC, G ;

WEIL, M ;

SOUBRANE, C ;

BANZET, P .

EUROPEAN JOURNAL OF CANCER, 1993, 29A :S2-S5

[8]

Legha S, 1992, P AN M AM SOC CLIN, V11, P343

[9]

Legha S, 1993, P AN M AM SOC CLIN, V12, P388

[10]

MACCLAY EF, 1989, CANCER, V63, P1292

← 1 2 →